NASDAQ$CLPT

ClearPoint Neuro Inc · Q2 2025 earnings

Q2 2025 earnings · · After market close · Investor relations

Briefing

ClearPoint Neuro Inc reported revenue of $10.9 million and a net loss of $11.3 million for the second quarter of 2026.

ClearPoint Neuro Inc posted total revenue of $10.9 million in Q2 2026, up 18% year-over-year, driven by growth in neurosurgery navigation and therapy products following the IRRAS acquisition. The company recorded a net loss of $11.3 million and an operating loss of $10.2 million amid higher operating expenses. Cash and cash equivalents stood at $29.4 million at quarter end.

  • Total revenue reached $10.9 million, with neurosurgery navigation and therapy revenue surging 62% to $5.6 million.
  • Gross profit increased 21% to $6.7 million, yielding a gross margin of 62%.
  • Net loss widened to $11.3 million as operating expenses rose due to IRRAS integration and team expansion.
  • Cash position declined to $29.4 million after $15.0 million used in operations during the first half of 2026.

Headline financials

Total Revenue

$9.22M

Previous: $7.86M+17.3%
EPS (adj)

-$0.38

Previous: -$0.16-137.5%
Capital Expenditures

-$274K

Previous: $0.00
Net Income

-$5.84M

Previous: -$4.41M-32.4%
Operating Income

-$5.68M

Previous: -$4.74M-19.9%
Gross Profit

$5.56M

Previous: $4.99M+11.4%
Cash & Equivalents

$41.5M

Previous: $32.8M+26.5%

Revenue & EPS history

ClearPoint Neuro · Revenue · Quarterly

$9.22M

Q2 2025+17.3%vs Q2 2024
Beat estimate in 9 of 15 quarters(60%)
ActualEstimate

Revenue by segment

ClearPoint Neuro · $10.9M total across 3 segments · Q2 2025

  • Neurosurgery navigation and therapy
    $5.55M
  • Biologics and drug delivery
    $4.03M
  • Capital equipment and software
    $1.3M

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports

Historical avg

-1.7%

Avg return

Earnings day

-1.7%

Avg return

5 days after

-2.3%

Avg return

30 days after

34%

15 / 44 earnings

Positive

+35.8%

Q2 2024

Best reaction

-24.1%

Q3 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q2 2025
Q1 2026-3.9%-12.1%+6.9%
Q4 2025-14.5%-14.8%+5.6%
Q3 2025-13.5%-8.3%-25.7%
Q1 2025-11.7%-7.6%-18.7%
Q4 2024-17.5%-22.1%-30.5%
Q3 2024-12.9%-16.9%+0.7%
Q2 2024+35.8%+46.6%+78.3%
Q1 2024+0.8%-1.3%-3.4%
Q4 2023+18.9%+18.6%+2.8%
Q3 2023-24.1%-14.3%+13.9%
Q2 2023-5.0%-8.9%-20.2%
Q1 2023-7.0%-8.8%-28.2%
Q4 2022-3.3%-4.5%-0.5%
Q3 2022-3.5%+2.6%-6.9%
Q2 2022+10.3%+9.6%-14.3%
Q1 2022+1.0%+17.0%+49.0%
Q4 2021-0.1%+6.2%+19.0%
Q3 2021-8.3%-11.3%-35.1%
Q2 2021-17.6%-20.2%-13.2%
Q1 2021+3.2%+4.5%+15.7%
Q4 2020-22.8%-14.0%-3.9%
Q3 2020+13.3%+25.3%+52.9%
Q2 2020-2.2%+5.3%+12.2%
Q1 2020-12.4%-14.9%+7.2%
Q4 2019+18.8%+13.6%-16.3%
Q3 2019-0.7%+2.3%+5.4%
Q2 2019+5.8%-1.2%-1.0%
Q1 2019+7.4%+10.6%+16.2%
Q4 2018-3.1%-3.1%-8.3%
Q3 2018-2.4%-4.9%-14.6%
Q2 2018-2.2%-6.6%-20.9%
Q1 2018-5.6%-7.4%-22.6%
Q3 2017+1.5%-8.0%-0.4%
Q2 2017-0.5%+8.4%+1.1%
Q1 2017+0.0%-3.9%-43.0%
Q3 2016+17.9%-3.8%-23.1%
Q2 2016-5.9%-15.3%-20.7%
Q2 2015-11.3%
Q1 2015-5.6%
Q2 2014+0.0%
Q1 2014+2.4%
Q2 2012+1.7%
Q1 2013-0.8%
Q3 2012+3.3%
Q1 2012
Q4 2011
Q3 2011
Q2 2011

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro